
|Articles|August 4, 2021
The Mainstream Patient: August 4, 2021
Author(s)Morgan Petronelli
This week’s edition of The Mainstream Patient features stories about purchasing non-toxic sunscreen, biologics for psoriasis, biotin for hair growth, "bacne", plus more.
Advertisement
In this week’s edition, Glamour reveals the top 7 questions to ask dermatologists about biologics. Also, Allure explains how biologics treat inflammatory skin diseases and details why biotin is most likely not the cause of hair growth. Hello Giggles dives into hair care products causing "backne" and how to get rid of dark armpits. Finally, Shape explains how to purchase non-toxic sunscreen.
Advertisement
Related to this article

From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.

Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.

Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.

Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
The Scariest Skin Care Trends Haunting Patients This Halloween
3
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
4
Improving Early Identification and Escalation of HS
5


